Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC).

Ravi Salgia,R. Waide Weaver,Michael McCleod,John R. Stille,S. Betty Yan,Stephanie Roberson,Oday Hamid,John Polzer,Amy Flynt,Eyas Raddad,David R. Spigel

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC).

2015

Ravi Salgia
R. Waide Weaver
Michael McCleod
John R. Stille
S. Betty Yan
Stephanie Roberson
Oday Hamid
John Polzer
Amy Flynt
Eyas Raddad
David R. Spigel

7567 Background: Small cell lung cancer (SCLC) can express CXCR4 chemokine receptor, and inhibition potentially synergizes with cytotoxic and targeted therapeutics in vitro in SCLC. Baseline CXCR4 ...

Keywords:

Pathology
Cell
Extensive Disease
Circulating tumor cell
CXCR4
Carboplatin/etoposide
Cancer research
CXCR4 antagonist
Lung cancer
Medicine
In vitro
non small cell
Chemokine receptor
Cytotoxic T cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations